Radiomics and Ki-67 index predict survival in clear cell renal cell carcinoma.


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
Oct 2023
Historique:
pmc-release: 01 10 2024
medline: 29 11 2023
pubmed: 2 7 2023
entrez: 2 7 2023
Statut: ppublish

Résumé

To develop and validate predictive models based on Ki-67 index, radiomics, and Ki-67 index combined with radiomics for survival analysis of patients with clear cell renal cell carcinoma. This study enrolled 148 patients who were pathologically diagnosed as ccRCC between March 2010 and December 2018 at our institute. All tissue sections were collected and immunohistochemical staining was performed to calculate Ki-67 index. All patients were randomly divided into the training and validation sets in a 7:3 ratio. Regions of interests (ROIs) were segmented manually. Radiomics features were selected from ROIs in unenhanced, corticomedullary, and nephrographic phases. Multivariate Cox models based on the Ki-67 index and radiomics and univariate Cox models based on the Ki-67 index or radiomics alone were built; the predictive power was evaluated by the concordance (C)-index, integrated area under the curve, and integrated Brier Score. Five features were selected to establish the prediction models of radiomics and combined model. The C-indexes of Ki-67 index model, radiomics model, and combined model were 0.741, 0.718, and 0.782 for disease-free survival (DFS); 0.941, 0.866, and 0.963 for overall survival, respectively. The predictive power of combined model was the best in both training and validation sets. The survival prediction performance of combined model was better than Ki-67 model or radiomics model. The combined model is a promising tool for predicting the prognosis of patients with ccRCC in the future. Both Ki-67 and radiomics have showed giant potential in prognosis prediction. There are few studies to investigate the predictive ability of Ki-67 combined with radiomics. This study intended to build a combined model and provide a reliable prognosis for ccRCC in clinical practice.

Identifiants

pubmed: 37393531
doi: 10.1259/bjr.20230187
pmc: PMC10546454
doi:

Substances chimiques

Ki-67 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20230187

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Tong Zhang (T)

Department of Radiology, Jinan City People's Hospital, Jinan, Shandong, China.

Ying Ming (Y)

Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Jingxu Xu (J)

Department of Research Collaboration, R&D center, Beijing Deepwise & League of PHD Technology Co.Ltd, Beijing, China.

Ke Jin (K)

Department of Research Collaboration, R&D center, Beijing Deepwise & League of PHD Technology Co.Ltd, Beijing, China.

Chencui Huang (C)

Department of Research Collaboration, R&D center, Beijing Deepwise & League of PHD Technology Co.Ltd, Beijing, China.

Mingguang Duan (M)

Department of Radiology, Jinan City People's Hospital, Jinan, Shandong, China.

Kaiguo Li (K)

Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, China.

Yuanwei Liu (Y)

Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, China.

Yonghui Lv (Y)

Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, China.

Jie Zhang (J)

Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, China.

Zhaoqin Huang (Z)

Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH